A mycobacterial growth inhibition assay (MGIA) for bovine TB vaccine development
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved..
Human tuberculosis remains a significant cause of mortality and morbidity throughout the world. The global economic impact of bovine TB is considerable. An effective vaccine would be the most cost-effective way to control both epidemics, particularly in emerging economies. TB vaccine research would benefit from the identification of an immune correlate of protection with which vaccines could be gated at both preclinical and clinical levels. In-vitro mycobacterial growth inhibition assays (MGIA) are functional assays that include most aspects of the complex host immune response to mycobacteria, and they may serve as functional immune correlates for vaccine development. We applied to cattle an MGIA that was developed for use with human and murine samples. Several technical difficulties were encountered while transferring it to the cattle model. However, our data demonstrate that the assay was not discriminatory in cattle and further work is needed before using it for bovine TB vaccine development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:106 |
|---|---|
| Enthalten in: |
Tuberculosis (Edinburgh, Scotland) - 106(2017) vom: 01. Sept., Seite 118-122 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pepponi, Ilaria [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BCG Vaccine |
|---|
| Anmerkungen: |
Date Completed 17.07.2018 Date Revised 29.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.tube.2017.07.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM274757982 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM274757982 | ||
| 003 | DE-627 | ||
| 005 | 20231225004159.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tube.2017.07.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0915.xml |
| 035 | |a (DE-627)NLM274757982 | ||
| 035 | |a (NLM)28802398 | ||
| 035 | |a (PII)S1472-9792(17)30106-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pepponi, Ilaria |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A mycobacterial growth inhibition assay (MGIA) for bovine TB vaccine development |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.07.2018 | ||
| 500 | |a Date Revised 29.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Human tuberculosis remains a significant cause of mortality and morbidity throughout the world. The global economic impact of bovine TB is considerable. An effective vaccine would be the most cost-effective way to control both epidemics, particularly in emerging economies. TB vaccine research would benefit from the identification of an immune correlate of protection with which vaccines could be gated at both preclinical and clinical levels. In-vitro mycobacterial growth inhibition assays (MGIA) are functional assays that include most aspects of the complex host immune response to mycobacteria, and they may serve as functional immune correlates for vaccine development. We applied to cattle an MGIA that was developed for use with human and murine samples. Several technical difficulties were encountered while transferring it to the cattle model. However, our data demonstrate that the assay was not discriminatory in cattle and further work is needed before using it for bovine TB vaccine development | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Bovine tuberculosis | |
| 650 | 4 | |a Correlate of protection | |
| 650 | 4 | |a Mycobacterial growth inhibition assay | |
| 650 | 4 | |a Vaccination | |
| 650 | 7 | |a BCG Vaccine |2 NLM | |
| 700 | 1 | |a Khatri, Bhagwati |e verfasserin |4 aut | |
| 700 | 1 | |a Tanner, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Villarreal-Ramos, Bernardo |e verfasserin |4 aut | |
| 700 | 1 | |a Vordermeier, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a McShane, Helen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Tuberculosis (Edinburgh, Scotland) |d 2001 |g 106(2017) vom: 01. Sept., Seite 118-122 |w (DE-627)NLM113651538 |x 1873-281X |7 nnns |
| 773 | 1 | 8 | |g volume:106 |g year:2017 |g day:01 |g month:09 |g pages:118-122 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.tube.2017.07.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 106 |j 2017 |b 01 |c 09 |h 118-122 | ||